Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 17066
Country/Region: Uganda
Year: 2016
Main Partner: World Vision
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $1,066,311 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $23,178
Care: TB/HIV (HVTB) $6,568
Care: Pediatric Care and Support (PDCS) $25,278
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $492,000
Testing: HIV Testing and Counseling (HVCT) $74,768
Sexual Prevention: Other Sexual Prevention (HVOP) $355,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $38,420
Treatment: Adult Treatment (HTXS) $44,638
Treatment: Pediatric Treatment (PDTX) $6,461
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age/Sex: <10 Female 2017 28
GEND_GBV Age/Sex: <10 Male 2017 16
GEND_GBV Age/Sex: 10-14 Female 2017 81
GEND_GBV Age/Sex: 10-14 Male 2017 16
GEND_GBV Age/Sex: 15-19 Female 2017 142
GEND_GBV Age/Sex: 15-19 male 2017 30
GEND_GBV Age/Sex: 20-24 Female 2017 147
GEND_GBV Age/Sex: 20-24 Male 2017 28
GEND_GBV Age/Sex: 25-49 Female 2017 59
GEND_GBV Age/Sex: 25-49 Male 2017 28
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 53
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 125
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 450
GEND_GBV Number of people receiving post-GBV care 2017 575
GEND_GBV Sum of Age/Sex Disaggregates 2017 141
HTS_TST Age/sex: <1 2017 580
HTS_TST Age/sex: 1-9 2017 1,919
HTS_TST Age/sex: 10-14 Female 2017 1,648
HTS_TST Age/sex: 10-14 Male 2017 1,655
HTS_TST Age/sex: 15-19 Female 2017 4,008
HTS_TST Age/sex: 15-19 Male 2017 5,899
HTS_TST Age/sex: 20-24 Female 2017 6,010
HTS_TST Age/sex: 20-24 Male 2017 8,849
HTS_TST Age/sex: 25-49 Female 2017 9,216
HTS_TST Age/sex: 25-49 Male 2017 13,566
HTS_TST Age/sex: 50+ Female 2017 801
HTS_TST Age/sex: 50+ Male 2017 1,179
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 2,896
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 2,906
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 20,035
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 29,493
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 55,330
HTS_TST Service Delivery Point (Facility): Index testing 2017 3,167
HTS_TST Service Delivery Point (Facility): Inpatient 2017 648
HTS_TST Service Delivery Point (Facility): Other PITC 2017 2,713
HTS_TST Service Delivery Point (Facility): Outpatient 2017 15,748
HTS_TST Service Delivery Point (Facility): Pediatric 2017 5,410
HTS_TST Service Delivery Point (Facility): PMTCT 2017 10,031
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 584
HTS_TST Service Delivery Point (Facility): VMMC 2017 17,029
HTS_TST Sum of Age/Sex disaggregates 2017 52,831
HTS_TST Sum of Aggregated Age/Sex <15 2017 5,802
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 49,528
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 55,330
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 74
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 83
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 142
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 99
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 214
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 146
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 329
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 225
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 29
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 20
HTS_TST_POS Test Result by Age: Positive: <1 2017 27
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 89
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 132
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 141
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 714
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 490
OVC_SERV Age/Sex: 18+ Female 2017 503
OVC_SERV Age/Sex: 18+ Male 2017 413
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 1,432
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 1,343
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 3,691
OVC_SERV Sum of Age/Sex disaggregates 2017 916
PMTCT_ART Already on ART at beginning of current pregnancy 2017 273
PMTCT_ART New on ART 2017 200
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 10,276
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 312
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 88
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 1
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 13
PMTCT_EID Sum of Infant Age disaggregates 2017 400
PMTCT_STAT By: Known positives at entry 2017 385
PMTCT_STAT By: Number of new positives identified 2017 116
PMTCT_STAT Number of new ANC and L&D clients 2017 10,540
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 10,276
PMTCT_STAT Sum of Positives Status disaggregates 2017 501
PP_PREV Aggregated Age/sex: <15 Female 2017 7,187
PP_PREV Aggregated Age/sex: <15 Male 2017 6,588
PP_PREV Aggregated Age/sex: 15+ Female 2017 8,428
PP_PREV Aggregated Age/sex: 15+ Male 2017 8,515
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 30,718
PP_PREV Total number of people in the target population 2017 33,039
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 35
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 2
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 63
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 101
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 101
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 197
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 19
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 60
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 118
TB_SCREENDX Screen Result: Screened Positive for TB 2017 48
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 1,256
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 647
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 296
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 260
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 2,459
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 10
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 134
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 14
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 243
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 401
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 401
TX_CURR Age/Sex: <1 2017 22
TX_CURR Age/Sex: <1-9 2017 132
TX_CURR Age/Sex: 10-14 Female 2017 217
TX_CURR Age/Sex: 10-14 Male 2017 185
TX_CURR Age/Sex: 15-19 Female 2017 63
TX_CURR Age/Sex: 15-19 Male 2017 19
TX_CURR Age/Sex: 20-24 Female 2017 289
TX_CURR Age/Sex: 20-24 Male 2017 129
TX_CURR Age/Sex: 25-49 Female 2017 841
TX_CURR Age/Sex: 25-49 Male 2017 468
TX_CURR Age/Sex: 50+ Female 2017 63
TX_CURR Age/Sex: 50+ Male 2017 31
TX_CURR Aggregated Age/Sex: <15 Female 2017 296
TX_CURR Aggregated Age/Sex: <15 Male 2017 260
TX_CURR Aggregated Age/Sex: 15+ Female 2017 1,256
TX_CURR Aggregated Age/Sex: 15+ Male 2017 647
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 2,459
TX_CURR Sum of age/sex disaggregates 2017 82
TX_CURR Sum of Aggregated Age/Sex <15 2017 556
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 1,903
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 2,459
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 40
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 35
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 462
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 240
TX_NEW By Age/Sex: <1 2017 2
TX_NEW By Age/Sex: 1-9 2017 20
TX_NEW By Age/Sex: 10-14 Female 2017 29
TX_NEW By Age/Sex: 10-14 Male 2017 24
TX_NEW By Age/Sex: 15-19 Female 2017 24
TX_NEW By Age/Sex: 15-19 Male 2017 5
TX_NEW By Age/Sex: 20-24 Female 2017 107
TX_NEW By Age/Sex: 20-24 Male 2017 48
TX_NEW By Age/Sex: 25-49 Female 2017 309
TX_NEW By Age/Sex: 25-49 Male 2017 174
TX_NEW By Age/Sex: 50+ Female 2017 22
TX_NEW By Age/Sex: 50+ Male 2017 13
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 777
TX_NEW Sum of Age/Sex disaggregates 2017 755
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 777
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 1,967
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 1,771
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 214
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 188
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 904
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 465
TX_PVLS Numerator: Indication: Routine 2017 1,771
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 237
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 207
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 1,005
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 518
TX_PVLS_den Denominator: Indication: Routine 2017 1,967
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 12
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 17
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 18
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 13
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 13
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 62
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 182
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 327
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 14
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 112
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 23
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 24
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 271
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 454
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 772
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 867
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 13
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 19
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 19
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 14
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 14
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 70
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 104
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 204
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 369
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 15
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 24
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 26
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 27
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 303
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 511
VMMC_CIRC By Age: 10-14 2017 6,640
VMMC_CIRC By Age: 15-19 2017 4,939
VMMC_CIRC By Age: 20-24 2017 2,385
VMMC_CIRC By Age: 25-29 2017 1,362
VMMC_CIRC By Age: 30-49 2017 1,362
VMMC_CIRC By Age: 50+ 2017 341
VMMC_CIRC By circumcision technique: Surgical VMMC 2017 17,029
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2017 17,029
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2017 17,029
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2017 14,305
Cross Cutting Budget Categories and Known Amounts Total: $310,000
Key Populations: MSM and TG $110,000
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Monitoring and evaluation of MSM/TG programs
Gender: Gender Based Violence (GBV) $100,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Gender: Gender Equality $100,000
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research